Glyxambi Approved for Type 2 Diabetes

February 2, 2015 2:36 PM

12 0

Glyxambi Approved for Type 2 Diabetes

The Food and Drug Administration (FDA) has approved Glyxambi (empagliflozin/linagliptin tablets; Boehringer Ingelheim and Eli Lilly) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments.

Glyxambi is the first treatment to combine a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet. Empagliflozin works by removing glucose through the urine by blocking blood glucose reabsorption in the kidney. Linagliptin works by i...

Read more

To category page